Liraglutide versus insulin detemir , the effective switch from intensive insulin therapy to the once-daily injection in patients with well controlled type 2 diabetes : a randomized controlled trial

Liraglutide versus insulin detemir , the effective switch from intensive insulin therapy to the once-daily injection in patients with well controlled type 2 diabetes : a randomized controlled trial - Liraglutide versus insulin detemir , the effective switch from intensive insulin therapy to the once-daily injection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007009

Enrollment

Registered

2012-01-04

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Detemir group 1.Intensive insulin therapy is discontinued. 2.The starting dose of insulin detemir is not changed. Add on sitagliptin (50 mg/day). 3.During the first 8 weeks, insulin detemir is titr

= FPG &lt

= 130 mg/dl. Liraglutide group 1.Intensive insulin therapy is discontinued 2.Starting at 0.3mg once daily with weekly increments of 0.3mg , reaching a final daily dose of 0.9mg by the end of the sec

160mg/dl , add on glimepiride 0.5mg and the dose is increased up to 1.0mg if necessary.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose HbA1c(JDS) were <= 6.9% on intensive insulin therapy with insulin dose of <= 30 units.

Exclusion criteria

Exclusion criteria: 1. Patients with history of diabetic ketoacidosis, or diabetic coma within 6 months prior to the study entry. 2. Patients with during pregnancy or lactation. 3. severe infection, before operation, severe trauma 4. Patients who received steroid therapy 5. Patients with history of cardiac failure. 6. Patients with renal insufficiency (serum creatinine > 1.5mg/dl (male) , > 1.3mg/dl (female), e-GFR < 50ml/min). 7. Patients with severe liver dysfunction. 8. Patients with type1 diabetes. 9. Patients with disorder of insulin secretion (serum C-peptide < 0.5ng/ml) 10. Patients who are hypersensitive to these medicines 11. Patients judged to be inappropriate by physicians in charge.

Design outcomes

Primary

Measure	Time frame
HbA1c at 0, 8, 16 and 24 weeks after administration of liraglutide or insulin detemir.	—

Secondary

Measure	Time frame
Fasting plasma glucose and self-monitoring blood glucose and body weight at 0, 8, 16 and 24 weeks after administration of liraglutide or insulin detemir , Diabetes treatment satisfaction questionnaire (DTSQ) , Frequency of side effects (digestive symptoms, hypoglycemia)	—

Countries

Japan

Contacts

Public ContactYuichiro Inoue

Yokohama City Unuversity Graduate School of Medicine Department of Endcrinology & Metabolism

hiroshic_w@yahoo.co.jp0457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026